DADC
HBIO icon

D.A. Davidson & Co’s Harvard Bioscience HBIO Stock Holding History

D.A. Davidson & Co’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-119
Closed -$4K – 2075
2013
Q3 		$4K Hold
119
– – ﹤0.01% 1593
2013
Q2 		$4K Buy
+119
New +$4.56K ﹤0.01% 1554

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCAM
F&C Asset Management Edinburgh, Scotland, United Kingdom $7.92B AUM 24.35% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.A. Davidson & Co's HBIO Position: Q4 2013 in Review

D.A. Davidson & Co sold out of Harvard Bioscience (HBIO) in Q4 2013, closing a stake of 119 shares — an estimated $4K sold.

D.A. Davidson & Co first reported a position in HBIO in Q2 2013 and held it in 2 quarters. The position peaked at $4K in Q3 2013. 77 funds tracked by Wall St. Rank hold HBIO as of Q4 2013.

  • D.A. Davidson & Co reported no remaining Harvard Bioscience position as of Q4 2013 after selling out during the quarter.
  • D.A. Davidson & Co sold 119 Harvard Bioscience shares in Q4 2013, an estimated $4K.
  • D.A. Davidson & Co first reported a position in Harvard Bioscience in Q2 2013 and held it in 2 quarters.
  • D.A. Davidson & Co's Harvard Bioscience position peaked at $4K in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2013.

Based on D.A. Davidson & Co's 13F filing for Q4 2013, filed 12 Feb 2014.